Biologics Market Transparency Act of 2022

Bill: 117-hr-7035
Sponsor: full_name: Rep. Manning, Kathy E. [D-NC-6]
Introduced: 2022-03-09
Policy area: Health
Latest action: action_date: 2022-03-10
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-03-09
action_desc: Introduced in House
text: <p><b>Biologics Market Transparency Act of 2022</b></p> <p>This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 7035 IN THE HOUSE OF REPRESENTATIVES March 9, 2022 Ms. Manning (for herself and Mr. Hudson ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.

1. Short title This Act may be cited as the Biologics Market Transparency Act of 2022 . 2. Prompt reports of marketing status by holders of approved applications for biological products (a) In general Section 506I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356i ) is amended— (1) in subsection (a)— (A) by striking The holder of an application approved under subsection (c) or (j) of section 505 and inserting The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act ; and (B) in paragraph (3), by striking or abbreviated application number and inserting , abbreviated application number, or biologics license application number ; and (2) in subsection (b)— (A) by striking The holder of an application approved under subsection (c) or (j) and inserting The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act ; and (B) in paragraph (2), by striking or abbreviated application number and inserting , abbreviated application number, or biologics license application number . (b) Additional one-Time report Subsection (c) of section 506I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356i ) is amended to read as follows: (c) Additional one-Time report Within 180 days of the date of enactment of the Biologics Market Transparency Act of 2022 , all holders of applications approved under subsection (a) or (k) of section 351 of the Public Health Service Act shall review the information in the list published under section 351(k)(9)(A) and shall submit a written notice to the Secretary— (1) stating that all of the application holder’s biological products in the list published under section 351(k)(9)(a) that are not listed as discontinued are available for sale; or (2) including the information required pursuant to subsection (a) or (b), as applicable, for each of the application holder’s biological products that are in the list published under section 351(k)(9)(a) and not listed as discontinued, but have been withdrawn from sale or never have been available for sale. . (c) Purple Book Subsections (d) and (e) of section 506I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356i ) are each amended— (1) by striking the list published under subsection 505(j)(7)(A) and inserting the list published under section 505(j)(7)(A) of this Act or section 351(k)(9)(A) of the Public Health Service Act, as applicable, ; and (2) by striking in accordance with subsection 505(j)(7)(C) and inserting in accordance with section 505(j)(7)(C) of this Act or section 351(k)(9)(B) of the Public Health Service Act (as applicable) .